SAN DIEGO–(BUSINESS WIRE)–Trefoil therapeutics announces third tranche of $28 million Series A financing based on achievement of clinical objectives
Author: Business Wire
National Vision Investor Relations Named to Institutional Investor’s 2022 All-America Executive Team
DULUTH, Ga.–(BUSINESS WIRE)– #eyecare–National Vision Holdings, Inc. (NASDAQ: EYE), the nation’s second largest optical retailer, announced that its investor relations leadership have been named to Institutional Investor’s 2022 All-America Executive…
Groupe Vision New Look annonce l'acquisition de Luxury Optical Holdings
MONTRÉAL & NEW YORK–(BUSINESS WIRE)–Groupe Vision New Look annonce aujourd’hui la conclusion d’un accord définitif en vue d’acquérir Luxury Optical Holdings (« LOH » ou la « société »). Avec sa présence existante dans le domaine de l’optique de luxe …
New Look Vision Group Announces the Acquisition of Luxury Optical Holdings
MONTREAL & NEW YORK–(BUSINESS WIRE)–New Look Vision Group announces today that it has entered into a definitive agreement to acquire New York-based Luxury Optical Holdings (“LOH” or the “Company”). With its existing luxury optical presence in Canada,…
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
WALDO Launches Doctor Partnership Program in the United States
NEW YORK–(BUSINESS WIRE)–WALDO, the innovative eyecare brand championing positive vision for all, is pleased to announce the launch of their doctor partnership program in the United States. WALDO is the first direct-to-consumer online contact lens co…
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today t…
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today reported positive topline results from VIVID, the comp…
Isarna Therapeutics Announces First Patient Enrolled in International Phase 2a Clinical Study in Ophthalmology Indications Wet AMD and DME
MUNICH–(BUSINESS WIRE)–Isarna Therapeutics today announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular …
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
National Vision Holdings, Inc. Increases Share Repurchase Authorization to $100 Million
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that its Board of Directors has authorized an increase by $50 million to $100 million in the Company’s share repurchase prog…
Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Device
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the j…
Global Leber Congenital Amaurosis Pipeline Insight Report 2021: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Leber Congenital Amaurosis – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. This Leber congenital amaurosis – Pipeline Insight, 2021 report provides comprehensive insights about…
National Vision Holdings, Inc. Announces Participation in the Morgan Stanley Virtual Global Consumer & Retail Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced the Company is scheduled to participate in a fireside chat at the Morgan Stanley Virtual Global Consumer & Retail Conference on Wednesday, December 1, 2021, …
Global Graves' Ophthalmopathy Clinical Trials Market Research Report, H2 2021 Review – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Graves’ Ophthalmopathy – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This clinical trial report provides an overview of the Graves’ Ophthalmopathy Clinical …
VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod dystrophy
PARIS–(BUSINESS WIRE)–VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both LCA and CORD.
ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
Evoq Technologies LLC Announces Launch of First Smartphone-Based Product for Retinal Health Testing
LAS VEGAS–(BUSINESS WIRE)–Evoq files with FDA and launches of first smartphone-based retinal health medical devices to fight blindness like age-related macular degeneration.
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Heru's Wearable Diagnostic, Health and Wellness Platform Honored with Prestigious CES Innovation Award by the Consumer Technology Association (CTA)
MIAMI–(BUSINESS WIRE)–Vision diagnostics and augmentation leader Heru Inc. has been named a CES® 2022 Innovation Awards Honoree in the Virtual & Augmented Reality category for re:Vive™ by Heru™, the company’s multi-modal, wearable diagnostic solu…